

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:	
Member Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Line of Business: <input type="checkbox"/> Medicare	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

REQUEST FOR EXPEDITED REVIEW: By checking this box and signing below, I certify that applying the 72 hour standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function.

Drug Name:	
Strength:	
Directions / SIG:	

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

<p>Q1. Is this a renewal request?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q2. FOR RENEWALS: Has the prescriber provided medical documentation to support the need for repeat treatment(s) occurring no sooner than every 3 months?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q3. FOR INITIAL REQUESTS: Is the patient greater than or equal to 18 years of age with a documented diagnosis of overactive bladder (OAB) with symptoms of urge urinary incontinence or urinary incontinence due to detrusor overactivity associated with a neurologic condition (e.g., spinal cord injury, multiple sclerosis)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q4. Has the patient had an inadequate response or intolerance to at least one anticholinergic medication (e.g., oxybutynin / oxybutynin ER, tolterodine / tolterodine ER, trospium / trospium ER, etc.)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q5. Is the patient greater than or equal to 18 years of age with a documented diagnosis of migraine headaches occurring greater than or equal to 15 days per month with headache lasting 4 hours a day or longer?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q6. Has the patient had an inadequate response or intolerance to at least 2 different classes of prophylactic medications (i.e., beta blockers [such as propranolol, metoprolol], amitriptyline, topiramate, valproic acid or its derivatives, verapamil)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:
<p>Q7. Does the patient have a documented diagnosis of sialorrhea associated with disorders of the nervous system or neurologic dysfunction?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>	
<p>Q8. Has the patient had an inadequate response or intolerance to at least 1 anticholinergic medication (e.g., glycopyrrolate)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>	
<p>Q9. Is the patient greater than or equal to 18 years of age with a documented diagnosis of severe primary axillary hyperhidrosis?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>	
<p>Q10. Is the patient greater than or equal to 18 years of age with a documented diagnosis of upper limb spasticity where the drug is being used to decrease the severity of increased muscle tone [in elbow flexors (biceps), wrist flexors (flexor carpi radialis and flexor carpi ulnaris), finger flexors (flexor digitorum profundus and flexor digitorum sublimis), or thumb flexors (adductor pollicis and flexor pollicis longus)] or lower limb spasticity where the drug is being used to decrease the severity of increased muscle tone [in ankle or toe flexors (gastrocnemius, soleus, tibialis posterior, flexor hallucis longus, flexor digitorum longus, brachialis, brachioradialis, pronator teres, pronator quadratus, lumbricals, interossei, flexor pollicis brevis, and opponens pollicis)]?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>	
<p>Q11. Is the patient greater than or equal to 16 years of age with a documented diagnosis of cervical dystonia where the drug is being used to reduce the severity of abnormal head position and neck pain?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>	
<p>Q12. Is the patient greater than or equal to 12 years of age with a documented diagnosis of blepharospasm or strabismus associated with dystonia?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>	
<p>Q13. Does the patient have a documented diagnosis of spasticity associated with cerebral palsy, hemifacial spasm, or laryngeal dystonia?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>	
<p>Q14. Is the prescribing physician a specialist for the condition (e.g., urologist for OAB or urinary incontinence; neurologist for migraine headaches; neurologist or physiatrist for upper limb spasticity, cervical dystonia, or hyperhidrosis; ophthalmologist for blepharospasm or strabismus)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>	
<p>Q15. Has the prescriber submitted documentation of the proposed injection site(s) and the dose that will be injected into each site?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>	

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:
----------------------	-------------------------

Q16. Is the dose in accordance with the recommend dosing below and occurring no sooner than every 3 months?
Overactive bladder – up to 100 units per treatment; Urinary incontinence – up to 200 units per treatment; Chronic migraine – up to 155 units per treatment; Upper limb spasticity – up to 400 units per treatment; Cervical dystonia – up to 300 units per treatment (up to 50 units per site); Hyperhidrosis – up to 100 units per treatment (up to 50 units per axilla); Blepharospasm – up to 200 units per treatment; Strabismus – up to 25 units per muscle per injection

Yes

No

Prescriber Signature

Date

2023 Medicare Prior Authorization Request